Concepedia

Gregory R. Bluemling

GR

Statistics

Publications

17

Citations

2.9K

H-Index

15

Active since

2016

Affiliations

Emory University(Current)

University of North Carolina at Chapel Hill

Centers for Disease Control and Prevention

Georgia State University

The University of Texas Medical Branch at Galveston

Gregory R. Bluemling is an author at Emory University specializing in molecular virology, infectious diseases, and antiviral pharmacology.

Publications per year

2016–2024

17

Publications

17

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan, Amy Sims, Shuntai Zhou et al. · Science Translational Medicine · 2020 · 1.2K citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl, Lisa E. Gralinski, Claire Johnson et al. · Nature · 2021 · 430 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Small-Molecule Antiviral β- <scp>d</scp> - <i>N</i> <sup>4</sup> -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Maria L. Agostini, Andrea J. Pruijssers, James D. Chappell et al. · Journal of Virology · 2019 · 354 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Märt Toots, Jeong-Joong Yoon, Robert M. Cox et al. · Science Translational Medicine · 2019 · 337 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +13

4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Julien Sourimant, Carolin M. Lieber, Megha Aggarwal et al. · Science · 2022 · 130 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +7

1–5 of 17